SaaS Metrics
Consumer Health Scrutiny
Pressure Measurement
AI Synthesis & Market Narrative
The accuracy of consumer blood pressure monitors is under scrutiny, and Samsung's discontinuation of the Vascular Load feature on Galaxy Watches in the US highlights challenges and potential regulatory pressures in consumer health measurement technologies.
Correlated Linguistic Patterns
["blood pressure monitor"
"lying to you"
"intraocular pressure"
"Samsung Discontinues Vascular Load Feature"
"Galaxy Watch"]
Driving Media Context
Degree of hypertension and subclinical coronary atherosclerosis in asymptomatic individuals without cardiovascular disease
Objective This study sought to evaluate the association between degree of hypertension and subclinical coronary atherosclerosis. Design and method We analy...
Study reveals how your sleeping position could be quietly destroying your vision
A study published in the British Journal of Ophthalmology found that sleeping with the head elevated on two standard pillows significantly increases intraocu...
Longitudinal associations of academic stress with eating related patterns, nutrition, somatic indicators, and depressive symptoms in university students: A study protocol
Introduction Academic stress (AS) can be understood as a multidimensional form of chronic stress that has been linked to adverse patterns across physical and...
Hackaday Europe 2026: Is Your Blood Pressure Monitor Lying To You?
Blood pressure is one of the so-called “vital signs” that medical practitioners use to determine the basic state of a patient in any given moment. It’s exact...
Samsung Discontinues Vascular Load Feature on Galaxy Watch in the US With One UI 9 Update
Samsung is removing the Vascular Load Labs feature from Galaxy Watches in the United States.
Thank you for being a Ghacks reader. The post Samsung Discontinu...
Sky Labs Showcases 'CART BP pro' for Potential Use in Drug Clinical Trials on Global Stage
BASEL, Switzerland and SEOUL, South Korea, July 3, 2026 /PRNewswire/ -- Sky Labs (CEO Jack Byunghwan Lee) announced on the 2nd that it introduced its data pl...
Sky Labs Showcases 'CART BP pro' for Potential Use in Drug Clinical Trials on Global Stage
BASEL, Switzerland and SEOUL, South Korea, July 3, 2026 /PRNewswire/ -- Sky Labs (CEO Jack Byunghwan Lee) announced on the 2nd that it introduced its data pl...
The Oura Ring 5 Just Started Shipping and Its New Health Features Are Unlike Anything a Wearable Has Done Before
Oura Ring 5 launched June 4, 2026, with blood pressure signals, lab result integration, GLP-1 tracking, and an IRB-approved brain health study. Starting at $...
Pressure Sensor Market to Reach USD 18.6 Billion by 2031, Growing at 6.4% CAGR, Says Wissen Research
SHERIDAN, Wyo., June 18, 2026 /PRNewswire/ -- The global pressure sensor market is projected to grow from USD 12.8 billion in 2025 to USD 18.6 billion by 203...
New | phs004618.v1.p1 | A Double Blind Randomized Controlled Trial to Assess the Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension (QUARTETUSA-BioLINCC)
A Double Blind Randomized Controlled Trial to Assess the Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension (QUARTETUSA-BioLINCC) (...